Clinical characteristics of patients with CML with chromosome 3 abnormalities
| Parameter . | Group A: inv(3)/t(3;3) (n=30) . | Group B: t(3;21) (n=20) . | Group C: other 3q26.2 (n=8) . | Group D: not 3q26.2 (n=37) . | Group E: del/add (n=21) . |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 14 (47%) | 15 (75%) | 5 (62%) | 22 (59%) | 13 (62%) |
| Female | 16 (53%) | 5 (25%) | 3 (38%) | 15 (41%) | 8 (38%) |
| Age, y | |||||
| Median | 54 | 52 | 58 | 49 | 49 |
| Range | 31-80 | 22-67 | 32-77 | 15-78 | 14-64 |
| Emergence phase | |||||
| CP | 13 (43%) | 4 (20%) | 2 (25%) | 17 (46%) | 3 (14%) |
| AP | 2 (7%) | 4 (20%) | 4 (50%) | 6 (16%) | 3 (14%) |
| BP | 15 (50%) | 12 (60%) | 2 (25%) | 14 (38%) | 15 (72%) |
| ACAs | |||||
| Sole | 14 (47%) | 7 (35%) | 2 (25%) | 15 (41%) | 2 (10%) |
| With others | 16 (53%) | 13 (65%) | 6 (75%) | 22 (59%) | 19 (90%) |
| TKI response | 26 | 15 | 6 | 31 | 17 |
| CCyR | 0 (0%) | 1 (7%) | 2 (33%)* | 13 (42%) | 4 (24%) |
| MMR | 0 (0%) | 1 (7%) | 1 (17%)* | 9 (29%) | 0 (0%) |
| Transplant after ACAs | 10 (33%) | 8 (40%) | 0 (0%) | 7 (19%) | 7 (33%) |
| F/U (m) | |||||
| Median | 13.3 | 13.6 | 10.3 | 31 | 5.6 |
| Range | 1.8-88 | 2.9-131.9 | 0.9-21.2 | 0.9-193 | 0.03-49.1 |
| Status at last F/U | |||||
| Dead | 24 | 19 | 7 | 28 | 17 |
| Persistent | 4 | 1 | 1 | 1 | 1 |
| Remission | 2 | 0 | 0 | 8 | 3 |
| Parameter . | Group A: inv(3)/t(3;3) (n=30) . | Group B: t(3;21) (n=20) . | Group C: other 3q26.2 (n=8) . | Group D: not 3q26.2 (n=37) . | Group E: del/add (n=21) . |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 14 (47%) | 15 (75%) | 5 (62%) | 22 (59%) | 13 (62%) |
| Female | 16 (53%) | 5 (25%) | 3 (38%) | 15 (41%) | 8 (38%) |
| Age, y | |||||
| Median | 54 | 52 | 58 | 49 | 49 |
| Range | 31-80 | 22-67 | 32-77 | 15-78 | 14-64 |
| Emergence phase | |||||
| CP | 13 (43%) | 4 (20%) | 2 (25%) | 17 (46%) | 3 (14%) |
| AP | 2 (7%) | 4 (20%) | 4 (50%) | 6 (16%) | 3 (14%) |
| BP | 15 (50%) | 12 (60%) | 2 (25%) | 14 (38%) | 15 (72%) |
| ACAs | |||||
| Sole | 14 (47%) | 7 (35%) | 2 (25%) | 15 (41%) | 2 (10%) |
| With others | 16 (53%) | 13 (65%) | 6 (75%) | 22 (59%) | 19 (90%) |
| TKI response | 26 | 15 | 6 | 31 | 17 |
| CCyR | 0 (0%) | 1 (7%) | 2 (33%)* | 13 (42%) | 4 (24%) |
| MMR | 0 (0%) | 1 (7%) | 1 (17%)* | 9 (29%) | 0 (0%) |
| Transplant after ACAs | 10 (33%) | 8 (40%) | 0 (0%) | 7 (19%) | 7 (33%) |
| F/U (m) | |||||
| Median | 13.3 | 13.6 | 10.3 | 31 | 5.6 |
| Range | 1.8-88 | 2.9-131.9 | 0.9-21.2 | 0.9-193 | 0.03-49.1 |
| Status at last F/U | |||||
| Dead | 24 | 19 | 7 | 28 | 17 |
| Persistent | 4 | 1 | 1 | 1 | 1 |
| Remission | 2 | 0 | 0 | 8 | 3 |
Age, age at ACA emergence; F/U (m): time from the emergence of ACAs to death or the last follow-up; Persistent, cytogenetic level and/or hematologic level; Remission, at least cytogenetic remission.
Transient response (see “Results” for detailed information).